Avastin for breast cancer, 2005-2011: Requiescat in pacem?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 12, 2011, Pages 1321-1323

  Burstein, Harold J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; EDITORIAL; HUMAN; MEDICARE; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT RESPONSE;

EID: 83755178089     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0112     Document Type: Editorial

References (2)

1. New drug approval: FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints. U.S. Government Accountability Office. Available at: http://www.gao.gov/products/GAO-09-866. Accessed November 22, 2011.
2. Nocera J. Why Doesn't No Mean No? New York Times. November 21, 2011. Available at: http://www.nytimes.com/2011/11/22/opinion/why-doesnt-no-mean-no. html. Accessed November 28, 2011.